Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial.
Hossein BehzadSina MashayekhiHila AshamParvin SarbakhshTaher Entezari-MalekiPublished in: Journal of cardiovascular and thoracic research (2024)
The results of this trial could not express the advantages of acute pretreatment with empagliflozin in preventing PCI-related myocardial injury.
Keyphrases
- percutaneous coronary intervention
- patients undergoing
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- coronary artery disease
- antiplatelet therapy
- coronary artery bypass grafting
- liver failure
- study protocol
- respiratory failure
- atrial fibrillation
- phase iii
- clinical trial
- coronary artery bypass
- phase ii
- randomized controlled trial
- double blind
- aortic dissection
- hepatitis b virus
- intensive care unit